



June 30, 2026

Kyle A. Diamantas  
Acting Commissioner of Food and Drugs  
U.S. Food and Drug Administration  
10903 New Hampshire Ave.  
Silver Spring, MD 20993

Dear Commissioner Diamantas,

At the FDA Task Force of Doctors for America, we know that trust in the FDA is vital for clinicians and patients to make individual medical choices. As physicians, we know that no drug is without risks, and therefore all drugs would be removed from the market if the standard is zero risk. Medicine is about making the right decision for the individual and we depend on a science-based FDA, with consistency in actions and the promise of regulatory clarity and regularity.

We are deeply concerned by the process surrounding the FDA's review of mifepristone Risk Evaluation and Mitigation Strategies initiated earlier this month, which makes good on a pledge by HHS Secretary Kennedy. The decision to review disregards reams of existing evidence on the medication that has been objectively reviewed and additionally found to be without undue political influence. The attached letter addresses concerns raised by Senators Cassidy and his colleagues, and summarizes the vast amount of data that currently exists as it pertains to safety and efficacy.

The conclusion is robust, and two-fold. First, mifepristone has been studied in far more detail than any other drug on the market, and found to meet the standards of reasonable safety and efficacy. Second, on the basis of internal FDA communications obtained through FOIA, the question of undue political influence has been soundly rejected. The study, [The US Food and Drug Administration's Regulation of Mifepristone](#), published in JAMA, a major peer-reviewed journal, meets the standard of acceptable scientific evidence.

If the FDA fails the test of presumptive regularity, one that it has clearly passed with previous decisions on mifepristone, the public and private trust will be irrevocably broken

Sincerely,

A handwritten signature in black ink that reads "Janet S. Krommes MD".

Jan Krommes, MD FACR  
Chair, FDA Task Force  
Doctors for America

A handwritten signature in black ink that reads "Angie Bakke".

Angie Bakke, MBA  
Executive Director  
Doctors for America